PLX Protalix BioTherapeutics Inc. (DE)

0.42
+0.01  (+2%)
Previous Close 0.42
Open 0.42
Price To Book -1.17
Market Cap 62691521
Shares 148,382,299
Volume 141,323
Short Ratio 5.16
Av. Daily Volume 432,891

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved May 1, 2012.
Taliglucerase alfa
Gaucher disease
Phase 3 dosing commenced October 2016. Enrollment to be finalized 2018.
Pegunigalsidase alfa (PRX-102)
Fabry disease
Phase 2 interim data released January 3, 2017. Full data released April 12, 2017. Company noted data were positive but results showed efficacy down on January data.
AIR DNase (PRX-110)
Cystic Fibrosis
Phase 2 data released March 13, 2018 - key endpoints met. Data presented at DDW Meeting - 67% of patients experienced a clinical response.
OPRX-106
Ulcerative Colitis
Phase 3 completion of enrolment announced December 17, 2018 with additional data due 2019.
Pegunigalsidase alfa (PRX-102) BRIDGE
Fabry disease
Phase 3 PK data from open label trial to be presented at WORLDSymposium February 7, 2019.
Pegunigalsidase alfa (PRX-102)
Fabry disease

Latest News

  1. Do Options Traders Know Something About Protalix (PLX) Stock We Don't?
  2. Protalix BioTherapeutics Reports 2018 Full Year Results and Provides Corporate Update
  3. Protalix Biotherapeutics, Inc. to Host Earnings Call
  4. Protalix BioTherapeutics to Postpone the 2018 Financial Results and Corporate Update Conference Call
  5. When Will Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Turn A Profit?
  6. Protalix BioTherapeutics to Hold Full-Year 2018 Financial Results and Corporate Update Conference Call on March 14, 2019
  7. The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut
  8. Protalix BioTherapeutics Presents Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium™ 2019
  9. The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs
  10. New Research: Key Drivers of Growth for Voya Financial, Conduent, Milacron, Altair Engineering, Genesis Healthcare, and Protalix BioTherapeutics — Factors of Influence, Major Initiatives and Sustained Production
  11. Protalix BioTherapeutics to Present Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium™ 2019
  12. Does The Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Share Price Tend To Follow The Market?
  13. Implied Volatility Surging for Protalix (PLX) Stock Options
  14. Moving Average Crossover Alert: Protalix BioTherapeutics
  15. Protalix BioTherapeutics Announces the Completion of Enrollment in the Phase III BRIDGE Clinical Trial of pegunigalsidase alfa for the Treatment of Fabry Disease
  16. Protalix (PLX) Reports Q3 Loss, Lags Revenue Estimates
  17. Protalix: 3Q Earnings Snapshot
  18. Protalix BioTherapeutics Reports 2018 Third Quarter Results and Provides Corporate Update
  19. Will Protalix (PLX) Report Negative Earnings Next Week? What You Should Know